Showing results (661-670 of 3,348) with videos related to

Sort By:
Pageof 335
Pharmacoeconomics|February 4, 2014
Methods for identifying the cost-effective case definition cut-off for sequential monitoring tests: an extension of Phelps and MushlinRoberta Longo, Paul Baxter, Peter Hall, et al.
Pharmacoeconomics|March 19, 2014
Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER)Rachel A Elliott, Koen D Putman, Matthew Franklin, et al.
Pharmacoeconomics|April 10, 2014
Cost and cost effectiveness of vaginal progesterone gel in reducing preterm birth: an economic analysis of the PREGNANT trialLaura T Pizzi, Neil S Seligman, Jason K Baxter, et al.
Pharmacoeconomics|April 10, 2014
Mapping EQ-5D utility scores from the PedsQL™ generic core scalesKamran A Khan, Stavros Petrou, Oliver Rivero-Arias, et al.
Pharmacoeconomics|February 20, 2008
Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approachesSun-Young Kim, Sue J Goldie
Pharmacoeconomics|April 24, 2008
Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision makingLieven Annemans
Pharmacoeconomics|November 17, 2016
The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic ReviewJuan Oliva-Moreno, Marta Trapero-Bertran, Luz Maria Peña-Longobardo, et al.
Pharmacoeconomics|November 17, 2016
Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalChristopher Carroll, Paul Tappenden, Rachid Rafia, et al.
Pharmacoeconomics|March 29, 2008
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov modelSimon Kreck, Jochen Klaus, Reiner Leidl, et al.
Pharmacoeconomics|November 16, 2018
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in ThailandBunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, et al.
Pageof 335